Supplementary Figures 1 - 6 from Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma

Autor: Heike Keilhack, Akira Yokoi, Kevin W. Kuntz, Roy M. Pollock, Toshimitsu Uenaka, Victoria M. Richon, Robert A. Copeland, Mikel P. Moyer, Richard Chesworth, Margaret Porter-Scott, Jesse J. Smith, Nigel J. Waters, Alejandra Raimondi, Christina J. Allain, Christine R. Klaus, Tim J. Wigle, Namita Kumar, Galina Kuznetsov, Mai Uesugi, Tadashi Kadowaki, Yonghong Xiao, Kuan-Chun Huang, Natalie M. Warholic, Yukinori Minoshima, Satoshi Kawano, Sarah K. Knutson
Rok vydání: 2023
Popis: PDF file - 811K, Fig. S1. Effects of EPZ-6438 on Gene Promoter H3K27 Methylation, Recruitment of PRC2 Components to Gene Promoters, and Cell Cycle, in WSU-DLCL2 Cells. Fig. S2: Effects of EPZ-6438 on Gene Expression in EZH2 Mutant Lymphoma Cell Lines. Fig. S3: Pharmacokinetic Profiles of EPZ-6438 in Rats and Mice. Fig. S4: EPZ-6438 Compound Levels in Plasma and WSU-DLCL2 Xenograft Tumor Homogenates from Mice Dosed for 7 or 28 Days. Fig. S5: In vivo Effects of EPZ-6438 in Lymphoma Xenograft Models. Fig. S6: Body Weights of Mice during Xenograft Efficacy Studies.
Databáze: OpenAIRE